Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 6/2016

01-12-2016

Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions

Authors: Lisete Ribeiro Teixeira, Murilo B. Dias, Roberta K. B. Sales, Leila Antonangelo, Vanessa A. Alvarenga, Juliana Puka, Evaldo Marchi, Milena Marques Pagliarelli Acencio

Published in: Lung | Issue 6/2016

Login to get access

Abstract

Background

Matrix metalloproteinases (MMPs) are responsible for the breakdown of the extracellular matrix and play an important role in the inflammatory processes of pleural exudates. The imbalance between MMPs and their inhibitors (TIMPs) is present in various pathological processes.

Objective

To evaluate the profile of MMPs and TIMPs in pleural effusions of different etiologies correlated with inflammatory markers.

Methods

The patients with pleural effusion due to tuberculosis (TB), cancer (CA) or transudate were prospectively evaluated. Pleural fluid was submitted to cytological, biochemical, cytokines, MMP, and TIMP analysis. Statistical analysis was performed using ANOVA and Spearman’s correlation, and p < 0.05 was considered significant.

Results

One hundred and fourteen patients were enrolled, 80 exudates (41 TB and 39 CA) and 34 transudates. The levels of MMP-8 and MMP-9 were higher in exudates compared to transudates. The level of MMP-8 was significantly higher in TB than in CA. TIMP-1 levels were higher in exudates. IL-6, VEGF, and TGF-β1 showed differences between exudates and transudates. However, IL-6 level was higher in TB than in CA. We found a significant correlation between MMPs and TIMPs with inflammation markers. MMP-1 was correlated with LDH levels. MMP-8 was correlated with LDH, total cell count, neutrophils, and ADA as well as MMP-1 levels. MMP-9 was correlated with IL-6, TGF-β1, and VEGF. TIMP-1 was correlated with MMP-9 and IL-6.

Conclusions

MMPs and TIMPs are expressed in pleural fluid of different etiologies and correlate with inflammatory mediators. MMPs may be useful in determining the cause of fluid, but more studies are needed to determine the spectrum of diseases associated with the various isoforms of MMPS and TIMPs.
Literature
1.
Light RW, Mac Gregor MI, Luchsinger PC et al (1972) Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77:507–513CrossRefPubMed
2.
Philip-Joét F, Alessi MC, Philip-Joét C et al (1995) Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 8:1352–1356CrossRefPubMed
3.
Antony VB, Godbey SW, Kunkel SL et al (1993) Recruitment of inflammatory cells to the pleural space. J Immunol 151:7216–7223PubMed
4.
Hurewitz AN, Zucker S, Mancuso P et al (1992) Human pleural effusions are rich in matrix metalloproteinases. Chest 102:1808–1814CrossRefPubMed
5.
Eickelberg O, Sommerfeld CO, Wyser C et al (1997) MMP and TIMP expression pattern in pleural effusions of different origins. Am J Respir Crit Care Med 156:1987–1992CrossRefPubMed
6.
Pritchard SC, Nicolson MC, Lloret C et al (2001) Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMp inhibition therapy. Oncol Rep 8:421–428PubMed
7.
D´Agostino P, Cameni AR, Caruso R et al (2003) Matrix metalloproteinase production in malignant pleural effusions after talc pleurodesis. Clin Exp Immunol 134:138–142CrossRef
8.
Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154PubMed
9.
Birkedal-Hansen H, Moore WG, Bodden MK et al (1993) Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4:197–250PubMed
10.
Murphy G, Docherty AJP (1992) The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7:120–125CrossRefPubMed
11.
Ma C, Tarnuzzer RW, Chengini N (1999) Expression of matrix metalloproteinases in tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-β1. Wound Repair Reqagen 7:477–485CrossRef
12.
Opdenakker G, Van den Steen PE, Van Damme J (2001) Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 22:571–579CrossRefPubMed
13.
Gomez DE, Alonso DF, Yoshiji H et al (1997) Tissue inhibitors of metalloproteinases: structure, function and biological functions. Eur J Cell Biol 74:111–122PubMed
14.
Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J 7:2062–2072PubMed
15.
Pugin J, Widmer M-C, Kossodo S et al (1999) Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 20:458–464CrossRefPubMed
16.
Leppert D, Leib SL, Grygar C et al (2000) Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with bloodbrain barrier damage and neurological sequelae. Clin Infect Dis 31:80–84CrossRefPubMed
17.
Sheen P, O´Kane CM, Chaudhary K et al (2009) High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur Respir J 33:134–141CrossRefPubMed
18.
Lijnen HR (2001) Plasmin and matrix metalloproteinases in vascular remodelling. Thromb Haemost 86:324–333PubMed
19.
Antony VB, Mohammed KA (1999) Pathophysiology of pleural space infections. Semin Respir Infect 14:9–17PubMed
20.
Streeter RM, Lukacs NW, Standiford TJ et al (1993) Cytokines and lung inflammation mechanisms of neutrophils recruitment to the lung. Thorax 48:765–769CrossRef
21.
Fujino S, Yokoyama A, Kohno N et al (1996) Interleukin 6 is an autocrine growth factor for normal human pleural mesothelial cells. Am J Respir Cell Mol Biol 14:508–515CrossRefPubMed
22.
Hoeben A, Landuyt B, Highley MS et al (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580CrossRefPubMed
23.
Fiorelli A, Vicidomini G, Di Domenico M et al (2011) Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg 12:420–424CrossRefPubMed
24.
Sack U, Hoffmann M, Zhao XJ et al (2005) Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 25:600–604CrossRefPubMed
25.
Seiscento M, Vargas FS, Antonangelo L et al (2007) Transforming growth factor beta-1 as a predictor of fibrosis in tuberculous pleurisy. Respirology 12:660–663CrossRefPubMed
26.
Sundararajan S, Babu S, Das SD (2012) Comparison of localized versus systemic levels of matrix metalloproteinases (MMPs), its tissue inhibitors (TIMPs) and cytokines in tuberculous and non tuberculous pleuritis patients. Hum Immunol 73:985–991CrossRefPubMedPubMedCentral
27.
Sepper R, Konttinen YT, Ding Y et al (1995) Human neophils collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest 107:1641–1647CrossRefPubMed
28.
Finlay GA, Russel KJ, McMahon H et al (1996) Matrix metalloproteinases in emphysema. Thorax 51:A51CrossRef
29.
Delacourt CM, Le Bourgeois M, d´Ortho MP et al (1995) Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sptum of patients with cystic fibrosis. Am J Respir Crit Care Med 152:765–774CrossRefPubMed
30.
Quiding-Jarbrink M, Smith DA, Bancroft GJ (2001) Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immunol 69:5661–5670CrossRef
31.
Price NM, Farrar J, Tran TT et al (2001) Identification of matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J Immunol 166:4223–4230CrossRefPubMed
32.
Jiang Y, Wang M, Celiker M et al (2001) Stimulation of mammary tumorigenesis y systemic inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 61:2365–2370PubMed
33.
Baker AH, George SJ, Zaltsman AB et al (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79:1347–1355CrossRefPubMedPubMedCentral
34.
Iglesias D, Alegre J, Aleman C et al (2005) Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusion. Eur Respir J 25:104–109CrossRefPubMed
35.
Saren P, Welgus HG, Kovanen PT (1996) TNF-alpha and IL-1 beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 157:4159–4165PubMed
36.
Fiorelli A, Morgillo F, Fasano M et al (2013) The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. Interact Cardiovasc Thorac Surg 16:263–269CrossRefPubMed
Metadata
Title
Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions
Authors
Lisete Ribeiro Teixeira
Murilo B. Dias
Roberta K. B. Sales
Leila Antonangelo
Vanessa A. Alvarenga
Juliana Puka
Evaldo Marchi
Milena Marques Pagliarelli Acencio
Publication date
01-12-2016
Publisher
Springer US
Published in
Lung / Issue 6/2016
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9945-5

Other articles of this Issue 6/2016

Lung 6/2016 Go to the issue

OriginalPaper

Intermittent Hypoxia Contributes to the Lung Damage by Increased Oxidative Stress, Inflammation, and Disbalance in Protease/Antiprotease System

OriginalPaper

Changes in Red Cell Distribution Width During Hospitalization for Community-Acquired Pneumonia: Clinical Characteristics and Prognostic Significance

Report

Radial Ultrasound-Assisted Transbronchial Biopsy: A New Diagnostic Approach for Non-Resolving Pulmonary Infiltrates in Neutropenic Hemato-Oncological Patients

OriginalPaper

Gemcitabine-Induced Autophagy Protects Human Lung Cancer Cells from Apoptotic Death

OriginalPaper

Inhaled Vitamin D: A Novel Strategy to Enhance Neonatal Lung Maturation

OriginalPaper

The Association Between Bone Mineral Density and Airflow Limitation in a Cohort of Fit Elderly Women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits